Opinion: Mifepristone court ruling makes drug development riskier for everyone

A US court ruling has made drug development riskier by reinstating an in-person dispensing requirement for mifepristone, a medication used by millions for over two decades. The Supreme Court granted a one-week stay, allowing the drug to be available again through mail and pharmacies. The ruling signals that even well-established medicines are vulnerable to judicial override of FDA regulatory decisions.